Martin Schmieg has been named CFO of Isolagen, the company said this week.
Schmieg was most recently CFO of Sirna Therapeutics, but left the Colorado-based company to pursue opportunities closer to his family and home in Philadelphia (see RNAi News, 4/8/2005).
Before joining Sirna, Schmieg was senior vice president and CFO at Advanced Bionics, where he helped oversee the company's sale to Boston Scientific, said Isolagen. Schmieg was also executive vice president of Cytometrics.
Archemix said this week that Michael Kallelis has been appointed vice president of manufacturing.
Before joining Archemix, Kallelis was executive vice president and general manager of Avecia Biotechnology. Prior to this, he co-founded and served as COO of Boston BioSystems, an oligonucleotide producer. Kallelis has also held positions with BioSepra and Millipore.
Paulette Gray has become director of the division of extramural activities of the National Cancer Institute, NCI said this week.
She had been the division's deputy director, then acting and deputy director, since 1997. The division of extramural activities coordinates all of NCI's extramural programs and grants.
Gray joined NCI in 1984 as a special review officer, moving to different positions from there. She holds a PhD in cellular and developmental biology and an MS in mycology from Atlanta University, and a BS in biology from Tuskegee University in Alabama.